A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. This phase III study (NCT01034462) evaluated the efficacy, the safety, and the tolerability of 40 to 120 mg/d of levomiln...

Descripción completa

Detalles Bibliográficos
Autores principales: Sambunaris, Angelo, Bose, Anjana, Gommoll, Carl P., Chen, Changzheng, Greenberg, William M., Sheehan, David V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Williams And Wilkins 2014
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047313/
https://www.ncbi.nlm.nih.gov/pubmed/24172209
http://dx.doi.org/10.1097/JCP.0000000000000060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047313/
https://www.ncbi.nlm.nih.gov/pubmed/24172209
http://dx.doi.org/10.1097/JCP.0000000000000060

Ejemplares similares